Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from CRSP

Crispr Therapeutics Rallies As It Plots Out Its Next Cancer Move Vs. Gilead, Novartis

Crispr Therapeutics said Thursday it will unveil the first data from human studies of its gene-edited lymphoma drug — and CRSP stock popped.

Investors Business Daily

Why This Analyst Has 'Little Conviction' On CRISPR's Upcoming Trial Data

Why This Analyst Has 'Little Conviction' On CRISPR's Upcoming Trial Data

RBC Capital Markets says it remains on the sidelines given commercial uptake for CRISPR Therapeutics' (NASDAQ: CRSP) sickle cell disease (SCD)/beta-thalassemia (BT) capped by preconditioning and has little conviction in BCMA/CD70 data within weeks. The analysts lowered its price target to $85 from $95 to reflect higher Opex, with a Sector Perform rating. As recently…

$100 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth This Much

$100 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth This Much

CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 13.5% on an annualized basis producing an average annual return of 25.08%. Currently, CRISPR Therapeutics has a market capitalization of $4.02 billion.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

What 4 Analyst Ratings Have To Say About CRISPR Therapeutics

Within the last quarter, CRISPR Therapeutics (NASDAQ:CRSP) has observed the following analyst ratings:

5 Beaten-Down Biotech Stocks Cathie Wood Loves

Renowned investor Cathie Wood of ARK Invest is known for her eye for stocks with enormous upside potential. Despite recent macro headwinds, the biotech industry is expected to grow tremendously in 2022, supported by strong demand for healthcare and medical products and increasing investments in R&D. Given these factors, Wall…

$1000 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth This Much

CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 14.85% on an annualized basis producing an average annual return of 28.2%. Currently, CRISPR Therapeutics has a market capitalization of $4.51 billion.

Here's How Much $1000 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth Today

CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 12.09% on an annualized basis producing an average annual return of 26.02%. Currently, CRISPR Therapeutics has a market capitalization of $5.12 billion.

inkl

Read news from The Economist, FT, and more,
with one subscription

Here's How Much $1000 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth Today

Here's How Much $1000 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth Today

CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 12.95% on an annualized basis.

Why Jim Cramer Believes Sirius XM Is Inexpensive

Why Jim Cramer Believes Sirius XM Is Inexpensive

On CNBC’s "Mad Money Lightning Round," Jim Cramer said CRISPR Therapeutics AG (NASDAQ: CRSP) is likely to "lose a lot of money.

CRISPR Therapeutics's Return On Capital Employed Insights

CRISPR Therapeutics's Return On Capital Employed Insights

Benzinga Pro data, CRISPR Therapeutics (NASDAQ:CRSP) reported Q4 sales of $12.90 million. Earnings fell to a loss of $141.25 million, resulting in a 11.09% decrease from last quarter.

Here's How Much You Would Have Made Owning CRISPR Therapeutics Stock In The Last 5 Years

Here's How Much You Would Have Made Owning CRISPR Therapeutics Stock In The Last 5 Years

CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 14.31% on an annualized basis.

People

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Vertex Pharmaceuticals Incorporated

RBC Capital Markets

Ginkgo Bioworks Holdings Inc

Crispr rapeutics

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Sickle Cell Disease

Places

285,143 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play